The purpose of this study was to investigate physical characteristics of two full field digital mammography (FFDM) systems (GE Senographe Essential and DS). Both are indirect conversion (x ray to light) alpha-Si flat panels coupled with a CsI(Tl) scintillator. The examined systems have the same pixel size (100 microm) but a different field of view: a conventional size 23 x 19.2 cm2 and a large field 24 X 30.7 cm2, specifically designed to image large breasts. In the GE Senographe Essential model relevant improvements in flat panel design were implemented and new deposition tools for metal, alpha-Si, and CsI(Tl) were introduced by GE. These changes in detector design are expected to be beneficial for advanced applications such as breast tomosynthesis. The presampling modulation transfer function (MTF), normalized noise power spectrum (NNPS), and detective quantum efficiency (DQE) were measured for a wide range of exposure (25-240 microGy) with a RQA-M2 technique (28 kVp with a Mo/Mo target/filter combination and 2 mm of additional aluminum filtration). At 1, 2, and at 4 lp/mm MTF is equal to 0.9, 0.76, and 0.46 for the conventional field detector and to 0.85, 0.59, and 0.24 for the large field detector. The latter detector exhibits an improved NNPS due to a lower electronic noise and a better DQE that reaches 60%. In addition a contrast-detail analysis was performed with CDMAM 3.4 phantom and CDCOM software: GE Senographe DS showed statistically significant poorer detection ability in comparison with the GE Senographe Essential. These results could have been expected, at least qualitatively, considering the relative DQE of the two systems.

Recently a new iterative reconstruction algorithm named Sinogram Affirmed Iterative Reconstruction (SAFIRE) has been released by Siemens. This algorithm works in the raw data domain with noise reduction as main purpose, providing five different strengths. In this study, the effect of SAFIRE on image quality has been investigated using selected phantoms and a comparison with standard filtered back projection (FBP) has been carried out. The following quantitative parameters have been evaluated: image noise, impact of different reconstruction kernels on noise reduction, noise power spectrum (NPS), contrast‐to‐noise ratio (CNR), spatial resolution, and linearity and accuracy of CT numbers. The influence of strengths on image quality parameters has also been examined. Results show that image noise reduction is independent of reconstruction kernel and strongly related to the strength of SAFIRE applied. The peak of NPS curve for SAFIRE reconstructions is shifted towards low frequencies; this effect is more marked at higher levels of strength. Contrast‐to‐noise ratio is always improved in SAFIRE reconstruction and increases with higher strength. At different dose levels SAFIRE preserves CT number accuracy, linearity, and spatial resolution, both in transversal and coronal planes. These results confirm that SAFIRE allows for image noise reduction with preserved image quality. First clinical data to validate this phantom analysis and confirm that commercially available iterative algorithms can play an effective role in dose containment.PACS number: 87.57.Q

No abstract

Background: Prostate-specific membrane antigen (PSMA) has gained high attention as a useful biomarker in the imaging evaluation of prostate cancer with positron emission tomography (PET) during recent years. [68Ga]-labeled Glu-urea-Lys(Ahx)-HBED-CC ([68Ga]-PSMA-HBED-CC) is a novel PSMA inhibitor radiotracer which has demonstrated its suitability in detecting prostate cancer. Preparation conditions may influence the quality and in vivo behavior of this tracer, and no standard procedure for the quality control (QC) is available. The aim of this study was to develop a new rapid and simple high-pressure liquid chromatography method of analysis for the routine QCs of [68Ga]-PSMA-HBED-CC to guarantee the high quality of the radiopharmaceutical product before release. Methods: A stepwise approach was used based on the quality by design concept of the International Conference of Harmonisation Q2 (R1) and Q8 (Pharmaceutical Development) guidelines in accordance with the regulations and requirements of European Association of Nuclear Medicine, Society of Nuclear Medicine, International Atomic Energy Agency, World Health Organization, and Italian Association of Nuclear Medicine and Molecular Imaging. The developed analytical test method was validated because a specific monograph in the pharmacopoeia is not available for [68Ga]-PSMA-HBED-CC. Results: The purity and quality of the radiopharmaceutical obtained according to the proposed method resulted high enough to safely administrate it to patients. An excellent linearity was found between 0.8 and 5 μg/mL, with a detection limit of 0.2 μg/mL. Assay imprecision (% CV) was <2%. Conclusions: The developed method to assess the radiochemical and chemical purity of [68Ga]-PSMA-HBED-CC is rapid, accurate, and reproducible, allowing routinely the use of this PET tracer as a diagnostic tool for imaging prostate cancer and also assuring patient safety.

Highlights A large number of high resolutions thorax CT scans collected for suspected SARS-CoV-2 infection. The use of an advanced software guarantees a great accuracy to calculate organ doses and effective doses. Monitoring in real time all the dosimetric aspects of COVID-19 outbreak; Cancer risk estimation according to the BEIR VII.